Global Alpha Emitter Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Alpha Emitter Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Alpha emitters are useful in the therapy of cancer. Alpha particles have been widely used in medical studies due to their limited range and high LET (deposit energy per unit length of route). Prostate cancer, melanoma, pancreatic cancer, ovarian cancer, thyroid, bone metastasis, lymphoma, endocrine tumors are among of the malignancies that are treated using alpha emitters. The treatment method employs a variety of radionuclides, including terbium (Tb-149), astatine (At-211), bismuth (Bi-212), actinium (Ac-225), radium (Ra-223), lead (Pb-212), bismuth (Bi -213). Increased awareness of the potential advantages of targeted alpha treatment, as well as the rising number of patients with cardiac and cancer diseases, are driving market growth. Alpha emitters plays important role in the cancer treatment.

Market Overview:

The latest research study on the global Alpha Emitter market finds that the global Alpha Emitter market reached a value of USD 702.36 million in 2022. It’s expected that the market will achieve USD 2006.64 million by 2028, exhibiting a CAGR of 19.12% during the forecast period.

Coronavirus disease 2019 (COVID19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2). Largely unknown before the outbreak began in Wuhan, China, in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. The COVID-19 pandemic has led to major changes in the clinical operations of radiology departments worldwide. In parallel with clinical preparedness activities, academic medical centers and universities were rushed to shut down scientific research activities to maximize social distancing and minimize the spread of infection to research staff and others with whom they might have contact.

The COVID-19 pandemic has created havoc worldwide; the outbreak has disrupted operations of healthcare systems globally. As a result, hospitals have ramped up testing efforts in an effort to save lives and minimize the spread of the virus. The financial challenges caused by COVID-19 forced governments across the globe to enforce budget cuts. Moreover, the pandemic resulted in lower patient volumes for nuclear medicine procedures and canceled elective procedures, creating a cash crunch for hospitals.

Increased awareness about the potential benefits of Alpha Emitter

Major drivers contributing to growth of the market are increasing incidences of cardiac & cancer ailments, increased awareness about the potential benefits of targeted alpha therapy and increasing availability of radiopharmaceuticals. Targeted cancer therapy or alpha (TAT) is gaining popularity as the prevalence of cancer and cardiovascular disease increases. Consumers are now more and more aware of the potential benefits of therapies aimed at curing such ailments. Alpha emitter radionuclide is considered to be a new approach to tackle cancer and related issues. Immunotherapy with radio with high efficiency short-range alpha particles is a surprising and promising therapeutic approach. The particles have an advantage in targeted therapy because of their exceptional ability to kill cells. Alpha emitters are currently used in the process of Targeted Alpha Therapy (TAT), where in an alpha emitter radionuclide exposes a certain amount of radiation dose to tumor cells, at a very early stage or in the state of metastasis, and destroy the respective cancer cells. In contrast to chemotherapy, TAT allows easy discrimination between the healthy cells and cancer cells. This is helpful in reducing the side effects associated with Chemotherapy. Alpha emitter provides many advantages when compared to beta emitters and photon therapy, making it an increasingly preferred mode of treatment. As a result, this has caught the attention of major players interested in capitalizing the market potential. Overall, targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Companies are now increasingly aware of the potential benefits of targeted therapies to treat several chronic ailments.

Short half-life

Shorter life of radiopharmaceuticals, need for high capital investment, stringent regulatory framework and reimbursement issues are the major factors impacting market growth. The short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent. The expiry of a radiopharmaceutical primarily depends on the half-life of the radioisotope and the content of the radionuclide. The non-utilization of radioisotopes within the prescribed shelf life causes radiation and chemical decomposition, reducing radiochemical purity to an unacceptable form, which may prove fatal during diagnosis and therapy. Moreover, nontargeted healthy cells are damaged, via radiation-induced death or stress of neighbouring cells. This is the disadvantage of alpha emitters therapy and restraining factor of the global market.

Region Overview:

In 2021, the share of the Alpha Emitter market in North America stood at 49.16%.

Company Overview:

Bayer AG is one of the major players operating in the Alpha Emitter market, holding a share of 56.97% in 2021.

Bayer AG

Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds and biotechnology products.

Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. The companys principal product candidates include Actimab-A, a Phase I/II clinical trial monoclonal antibody for the treatment of acutemyeloid leukemia in elderly patients; and Iomab-B that has completed a Phase I/II design trial used to condition the bone marrow of patients by destroying blood cancer cells in their bone marrow. It also offers BC8-Y-90 and BC8-SA product candidates, which are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center. The company was founded in 2000 and is based in New York, New York.

Segmentation Overview:

As for product types, the Radium (Ra-223) segment held the largest market share in 2021.

Application Overview:

In the Alpha Emitter market, 86.09% of the total value was generated through the Prostate Cancer segment by application in 2021.

Prostate Cancer

Prostate cancer is a form of cancer that begins in the gland cells of the prostate, which is found only in males. The prostate is a gland in the male reproductive system that surrounds the urethra just below the bladder.

Melanoma

Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control. Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can then spread to other areas of the body.

Pancreatic Cancer

Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. Pancreatic cancer can develop from two kinds of cells in the pancreas: exocrine cells and neuroendocrine cells, such as islet cells. Pancreatic cancer is hard to catch early.

Ovarian Cancer

Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Ovarian cancer is a growth of cells that forms in the ovaries. The cells multiply quickly and can invade and destroy healthy body tissue.

Thyroid

Thyroid cancer is a solid tumor cancer that usually shows up as a nodule, or mass, in the thyroid gland, which is located at the front base of your throat. It occurs when rogue cells reproduce too rapidly for the immune system to control. There are four main types of thyroid cancer. These are papillary, follicular, medullary, and anaplastic.

Bone Metastasis

Bone metastasis occurs when cancer cells spread from their original site to a bone. Nearly all types of cancer can spread (metastasize) to the bones. But some types of cancer are particularly likely to spread to bone, including breast cancer and prostate cancer.

Lymphoma

Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The lymphatic system includes the lymph nodes (lymph glands), spleen, thymus gland and bone marrow. Lymphoma can affect all those areas as well as other organs throughout the body.

Endocrine Tumors

Endocrine cancers are those found in tissues of the endocrine system, which includes the thyroid, adrenal, pancreas, parathyroid, and pituitary glands. Endocrine tumors are rare and often difficult to diagnose.

Key Companies in the global Alpha Emitter market covered in Chapter 3:

Orano Med
Cellectar Biosciences
Bayer AG
Actinium Pharmaceuticals
RadioMedix
Telix Pharmaceuticals
Fusion Pharmaceuticals
Alpha Tau Medical

In Chapter 4 and Chapter 14.2, on the basis of types, the Alpha Emitter market from 2018 to 2029 is primarily split into:

Terbium (Tb-149)
Astatine (At-211)
Bismuth (Bi-212)
Actinium (Ac-225)
Radium (Ra-223)
Lead (Pb-212)
Bismuth (Bi -213)

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Alpha Emitter market from 2018 to 2029 covers:

Prostate Cancer
Melanoma
Pancreatic Cancer
Ovarian Cancer
Thyroid
Bone Metastasis
Lymphoma
Endocrine Tumors
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)